BioArctic Achieves Milestone Sales with Leqembi
In an exciting update, BioArctic AB's (publ) strategic partner, Eisai, has announced remarkable sales success for Leqembi, reporting total revenues of 18 billion yen for the third quarter of 2025. This achievement represents a significant rise in royalties paid to BioArctic, amounting to SEK 117.2 million, reflecting a 68 percent increase compared to the same quarter last year.
Impact of Leqembi’s Sales Performance
Leqembi, also known as lecanemab, has become a pivotal treatment option for Alzheimer's disease, particularly for individuals in early stages of the condition. BioArctic is poised to publish its detailed financial outcomes for Q3 2025 soon, providing deeper insights into how this revenue growth aligns with their operational strategies and market expectations.
About Lecanemab (Leqembi)
Lecanemab is a product of extensive collaboration between BioArctic and Eisai, designed to combat Alzheimer's disease by targeting amyloid-beta forms. It has gained regulatory approval across 51 countries, including significant markets like the United States and Japan, for treating patients diagnosed with Mild Cognitive Impairment (MCI) and early dementia stages. This global acceptance signifies its importance in addressing cognitive health issues.
Clinical Research and Development
The commitment to research is evident in Eisai's ongoing Phase 3 clinical study, AHEAD 3-45, which aims to evaluate lecanemab's effectiveness in individuals with preclinical Alzheimer’s disease. This comprehensive study is part of a rigorous public-private partnership, enhancing the prospects for future approvals and market expansion.
Collaboration History Between BioArctic and Eisai
BioArctic and Eisai have built a robust partnership since 2005, focusing on the collaboration for Alzheimer’s treatment innovations. Their joint efforts have led to several pivotal agreements that have fueled the development of lecanemab. Notably, the agreements cover the commercialization strategies, ensuring BioArctic can leverage its strengths in the Nordic markets without incurring R&D costs.
Future Directions for BioArctic
The future appears bright for BioArctic as it aligns its commercial strategies with the growing acceptance of lecanemab. The company continues to develop additional projects targeting neurodegenerative diseases, showcasing a commitment not just to Alzheimer's but also conditions such as Parkinson’s disease and ALS.
Innovation at the Forefront
By utilizing its proprietary BrainTransporter™ technology, BioArctic has the potential to improve treatment delivery through the blood-brain barrier. This innovative approach aims at enhancing the efficacy of antibodies and reflecting BioArctic's dedication to pioneering new medical solutions.
Frequently Asked Questions
What are the sales figures for Leqembi in Q3 2025?
Leqembi achieved total sales of 18 billion yen during the third quarter of 2025.
Who are the partners collaborating on Leqembi?
BioArctic AB collaborates with Eisai and Biogen in the development and commercialization of Leqembi.
What are the approval statuses of lecanemab?
Lecanemab is approved in 51 countries for treating early Alzheimer's disease and is under review in 9 countries.
What studies are ongoing related to lecanemab?
The AHEAD 3-45 clinical study is a four-year research project focusing on individuals with preclinical Alzheimer's disease.
How does BioArctic support its collaboration with Eisai?
BioArctic supports its collaboration by preparing for commercialization in the Nordics while having no development costs for lecanemab.
